Temporary prostatic stenting and androgen suppression: a new minimally invasive approach to malignant prostatic retention.
Urinary retention secondary to carcinoma of the prostate is usually treated by 'channel' transurethral resection of the prostate either performed alone or in combination with hormone manipulation. The combination of temporary prostatic stenting and androgen suppression may reduce the morbidity and mortality associated with this treatment. We report on our initial experience using the combination of a temporary prostatic stent with the oral anti-androgen Flutamide in 10 patients with urinary retention or severe bladder outflow obstruction secondary to prostatic carcinoma. Eight of the ten patients successfully voided and maintained normal voiding after stent removal. There were two treatment failures requiring prostatic resection. We believe the cost of stenting and medication is entirely justified by patient preference and clearance of hospital beds.
Anson
K M
KM
Department of Urology and Minimally Invasive Surgery, Whittington Hospital, Highgate Hill, London, UK.
Barnes
D G
DG
Briggs
T P
TP
Watson
G M
GM
Miller
R A
RA
D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications / Q000628:therapy*; D015607:Stents; D016055:Urinary Retention / Q000209:etiology / Q000628:therapy*
D005485:Flutamide